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ABSTRACT
DANIELLE M.FULBRIGHT: Dopamine D2 Receptor Antagonist Raclopride’s Effects on
Core Temperature Alone and During Methamphetamine Administration at Varying Ambient
Temperatures
(Under the direction of Dr. Karen Sabol)
Rationale Methamphetamine(METH)induces hypothermia at cool (18°) ambient
temperatures and hyperthermia at neutral (24°) and warm (30°) ambient temperatures. Our
objective was to determine if pretreatment with raclopride(RAC),a dopamine D2 receptor
antagonist would alter METH-induced core temperature changes.
Methods Two experiments were conducted. In Experiment 1, RAC was administered alone,
to determine its effects, if any, on core temperature. In Experiment 2,rats received
pretreatment injections of0.3, 0.6, or 1.2-mg/kg RAC or a saline control (sal) injection; rats
then received injections of 10 mg/kg METH or sal injection. In both Experiment 1 and 2,
core temperature measurements were made telemetrically in three different ambient
temperatures(18,24, or 30° C)
Results Experiment 1: Treatment with the 1.2 mg/kg dose of RAC at 18° C caused
hypothermia at 30,45, and 75 minutes post- treatment. RAC had no effect on core
temperature at either 24° or 30° C.
Experiment 2: Treatment with METH at 18° C caused hypothermia. At 18° C, all three RAC
(0.3, 0.6,1.2 mg/kg)treatments enhanced the METH-induced hypothermia at 60 minutes
post-treatment. Treatment with METH at 24° C and 30° caused hyperthermia. At 24° C,the
1.2 mg/kg RAC dose attenuated the METH-induced hyperthermia, at 60 minutes post
treatment. The 0.3 mg/kg dose and the 0.6 mg/kg dose had no effect on the METH-induced
hyperthermia. At 30° C,the 0.6 mg/kg RAC dose attenuated the METH-induced
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hyperthermia at 60 minutes post-treatment. Neither the 0.3 mg/kg dose nor the 1.2 mg/kg
doses of RAC had an effect on the METH-induced hyperthermia at 30° C.
Conclusions Experiment 7.- At 18° C,the 1.2 mg/kg dose of RAC caused an unexpected
decrease in core temperature. This result is inconsistent with literature findings. In the
hterature, D2 agonists caused a decrease in core temperature at room temperature (24° C),
and D2 antagonists attenuated these hypothermic effects. Our result of RAC-induced
hypothermia suggests the D2 receptor is involved m heat production at cool(18° C)ambient
temperatures.
Experiment 2;Pre-treatment with RAC enhanced METH-induced hypothermia at 18° C,and
lowered METH-induced hyperthermia at 24° C, which is inconsistent with the above
mentioned D2 direct agonist literature that suggests a D2 antagonist should increase core
temperature. While inconsistent with the direct agonist data, the attenuation of METHinduced hyperthermia at 24° C by 1.2 mg/kg RAC was consistent with D2 antagonist/METH
literature. The enhanced METH-induced hypothermia at 18° C and attenuated METHinduced hyperthermia at 24° C may be due to the interaction of dopamine, serotonin, and
norepinephrine following METH administration.
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Introduction
Methamphetamine(METH)and its analogs(amphetamine(AMPH)and 3,4Methylenedioxymethamphetamine(MDMA))are drugs of abuse. METH,in particular, is a
stimulant that can be made in illegal laboratories from easily attainable and inexpensive
products (National Institute on Drug Abuse 1999). METH analog misuse is a major concern
in the United States, as METH and its analogs have become the most widely available and
misused amphetamine-type stimulants worldwide(Meredith et al. 2005: United Nations
Office on Drugs and Crime, 2003). METH and its analogs affect many areas ofthe body.
including core temperature control.
METH and Analogs* Effects on Core Temperature
Numachi, et al(2007), Green et al(2003), Sugimoto et al (2001), Meehan et al
(2002), Broening et al (2005), Bronstein and Hong (1995), Bowyer et al(1994), Malberg and
Seiden (1998), Dafters(1995), Yehuda and Wurtman(1972), and Myles et al(2008)found
multiple doses of METH or an analog(MDMA,PCA,or AMPH)cause hyperthermia wdien
administered at neutral(24-26° C)and warm (28-37 °C)ambient temperatures. Myles et al
(2008), Green et al (2005), Yehuda and Wurtman (1972), Dafters(1995), and Malberg and
Seiden (1998)found multiple doses of METH or an analog(MDMA,AMPH,or PCA)
caused hypothermia when administered at cool(4-20° C)ambient temperatures. While not a
drug ofabuse, p-chloroamphetamine(PCA)is a METH analog that affects core temperature
(Sugimoto et al. 2001).
The area between the cool ambient temperature category and the neutral ambient
temperature does not show a concrete boundary, but rather a range of ambient temperatures
in which METH and its analogs affect core temperature differently depending on the
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experimental conditions. The experimental condition that seems to have the most impact on
the results is the temperature-recording device.
Studies(Meehan et al. 2001; Yehuda and Wurtmanl972)that used a rectal probe
reported METH-induced hyperthermia at 20-22° C while studies(Myles et al. 2008: Malberg
and Seiden 1998)that used a telemetric temperature sensor reported METH-induced
hypothermia at 20°C. The use of a rectal probe is thought to cause an unwanted increase in
core temperature due to animal stress that is independent of METH or an analog (Matthew,
1997). Since Myles et al.(2008)and Malberg and Seiden(1998)both reported METH
induced hypothermia at 20° C using telemetry, their data suggest the ambient temperature
boundary between stimulant-induced hypothermia and hyperthermia is above 20° C.
METH Mechanism ofAction
METH and its analogs’ effects on core temperature may be related to their effects on
the monoamines, as the monoamines are important in core temperature control(Lopachin
and Rudy 1982). METH use increases monoamine (serotonin, dopamine, and
norepinephrine) release in laboratory animals(Bowyer et al, 1994; Rothman and Baumann
2003). In the case of dopamine, METH reverses the action ofthe uptake transporter of a
dopamine neuron. Under normal conditions, the transporter would take dopamine back up
into the neuron, but the METH-induced reversal changes the action ofthe transporter and it
pushes dopamine out, resulting in a large amount of dopamine in the synapse (Arnold et al.
1977; Azzaro et al.l974). For this study, we are interested in dopamine, its effects on core
temperature, and the dopamine system’s effects on METH-induced temperature change.
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Neurotransmitter Interaction
Although we are focusing on METH’s effects on the dopamine system, it is important
to realize that METH and its analogs affect the release ofnot only dopamine, but also
serotonin and norepinephrine. Each ofthe analogs affects neurotransmitter release in a
slightly different way. The rank order of METH and AMPH-induced neurotransmitter release
is norepinephrine > dopamine > serotonin, meaning norepinephrine release is highest,
followed by dopamine, which is followed by serotonin(Rothman et al. 2001; Crespi et al.
1997; Wee et al. 1997). In fact, AMPH causes more dopamine release than METH(Rothman
et al. 2001).
For MDMA and PCA,on the other hand,the rank order of neurotransmitter release is
serotonin > both dopamine and norepinephrine, meaning serotonin release is higher than
dopamine and also higher than norepinephrine (Johnson et al. 1987; Rothman and Baumann
2003; Sanders-Bush et al. 1975; Crepsi et al. 1997).
As stated above, all three monoamines are involved in temperature regulation.
Dopamine and serotonin are important neurochemicals that aid the central nervous system in
temperature control(Gudelsky et al. 1986; Ootsuka et al. 2007), while norepinephrine aids
both the central and peripheral nervous system in temperature control(Depocas et al. 1978).
We are investigating the dopamine system to determine its effects on METH-induced core
temperature change, in order to eventually understand the complex relationship between
METH induced core temperature changes and neurotransmitter release.
Dopamine
Dopamine is thought to affect core temperature in most species of animals, including
rats(Clark et al. 1985). In fact, administration of dopamine causes a temperature decrease
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(hypothermia)in rats (Clark et al. 1985). Dopamine has several receptor subtypes, but two in
particular(D1 and D2)are unphcated as receptors involved in controlling core temperature
(Salmi et al. 1993).
D1 Receptor Sub-Type
D1 receptor agonist A 68930 produced a dose dependent hypothermia in the rat
(Salmi et al. 1993). D1 partial agonist SKF 38393 alone had no effect on core temperature at
24° C, but it prevented the hypothermia caused by A 68930(Salmi et al. 1993). D1
antagonist SCH 23390 alone had no effect on core temperature at 24° C, but it also prevented
the hypothermia caused by A 68930(Salmi et al. 1993).
D2 Receptor Sub-Type
Several D2 receptor agonists, quinpirole, 7-OH-DPAT,and TNPA,caused a dose
dependent hypothermia at room temperature (22-24° C)in the rat(Salmi et al. 1993; Elytab
et al. 2001;Chaperon et al. 2003). RAC,a D2 receptor antagonist, alone had no effect on core
temperature, but it prevented the hypothermia caused by quinpirole at room temperature (2224° C)(Salmi et al. 1993; Elytab et al. 2001). L-741,626, another D2 antagonist, prevented
the hypothermia caused by TNPA at 24° C(Chaperon et al, 2003).
D1 and D2Receptor Sub-Type Interaction
Interestingly, D1 receptor antagonist SCH 23390, which prevented the hypothermia
caused by the D1 agonist A 68930, had no effect on the hypothermia caused by the D2
receptor agonist quinpirole (Salmi et al. 1993)Also, the D2 receptor antagonist RAC, which
attenuated the hypothermia caused by the D2 agonist quinpirole, had no effect on the
hypothermia caused by the D1 receptor agonist A 68930(Salmi et al. 1993). Therefore, the
dopamine D1 and D2 receptor sub-types seem to be distinct from each other, at least as far as
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temperature is concerned. For this study, we decided to focus on the dopamine D2 receptor
subtype.
METH Analogs and D2 Receptor Sub-Type
At neutral ambient temperatures(24-26.5° C), Bowyer et al(1994)and Broening et al
(2005) were able to attenuate METH-induced hyperthermia with D2 antagonists(haloperidol
and eticlopride, respectively). Yehuda and Wurtman(1972) were able to attenuate AMPHinduced hyperthermia by using pimozide, another D2 antagonist.
However, Bronstein and Hong(1995) were not able to attenuate METH-induced
hyperthermia with the D2 antagonist sulpiride. Similarly, Meehan et al(2001)and Sugimoto
et al (2001) were not able to attenuate MDMA and PCA-induced hyperthermia with D2
antagonists (remoxipride and sulpiride, respectively).
At cool (4-20°C) ambient temperatures. Green et al(2005)and Yehuda and Wurtman
(1972) were able to attenuate MDMA and AMPH-induced hypothermia using D2
antagonists,(remoxipride, haloperidol, and pimozide respectively).
The literature concerning the cool (4-20° C)ambient temperature category seems to
agree that blockade ofthe D2 receptor with a D2 antagonist will attenuate METH analoginduced hypothermia. However,some obvious discrepancies exist in the literature concerning
the neutral (24-26.5° C)and warm (30° C)ambient temperature data. The results of Bowyer
et al.(1994), Broening et al.(2005)and Yehuda and Wurtman(1972)give strong evidence
that blockade ofthe D2 receptor with a D2 receptor antagonist will attenuate METH induced
hyperthermia at neutral (24-26.5° C)ambient temperatures. However,compelling evidence
exists in Sugimoto et al.(1998), Bronstein and Hong(1995), and Meehan et al.(2001)that
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blockade with a D2 receptor antagonist will not attenuate METH-induced hyperthermia at
neutral (24-26.5° C)ambient temperatures.
Some experimental differences exist that could be the cause ofthese discrepancies.
Four analogs(METH,MDMA,PCA,AMPH)were used in these studies, and as discussed
above, neurotransmitter release is affected differently by each ofthese analogs.
Neurotransmitter release, in turn, affects core temperature. Similarly, each ofthe analogs was
administered in very different doses, which could also cause the discrepancies in the results.
Also, as discussed above, method oftemperature measurement(telemetry versus rectal
measurement) can affect core temperature.
Different D2 antagonists were used by most ofthe studies, which could cause a
discrepancy; however, Sugimoto et al.(1998)and Bronstein and Hong(1995)used the same
antagonist (sulpiride) at different doses(10 mg/kg and 20 mg/kg respectively) and with
different analogs(PCA and METH respectively) and had the same result. While these results
suggest the specific D2 antagonist does not affect core temperature, only two studies used the
same antagonist and achieved the same result. Broening et al.(2005) used eticlopride and
attenuated METH-induced hyperthermia, while Bronstein and Hong(1995)used sulpiride
and did not attenuate METH-induced hyperthermia, indicating differences in D2 antagonist
do have an effect on METH-induced core temperature changes.
Other experimental differences exist that do not seem to be the cause of the
discrepancies in the literature. Different strains of animals(Sprague-Dawley versus Dark
Agouti rats), different housing conditions (individual versus group), and different modes of
injection (ip versus sc) were used by Myles et al.(2008), Yehuda and Wurtman(1972)and
Malberg and Seiden (1998) but these studies had similar results. While these studies had
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several differing experimental conditions, they achieved the same result, suggesting these
parameters do not explain the experimental discrepancies.
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Hypothesis
RAC-induced Temperature Changes
We hypothesize RAC will have no effect on core temperature at 18,24,or 30° C
based on the findings of Chaperon et al.(2003), who found the D2 antagonist L-741,626 had
no effect on core temperature at 24° C and Salmi et al.(1993)and Elytab et al.(2001), who
found RAC had no effect on core temperature at 24° C.
METH-induced Temperature Changes
We hypothesize that METH will cause a decrease in core temperature at cool(4-22°
C)ambient temperatures(Green et al. 2005; Yehuda and Wurtman 1972), an increase in core
temperature at neutral(22-26.5° C)ambient temperatures(Broening et al. 2005; Bronstein
and Hong 1995; Bowyer et al. 1994; Dafters 1995; Green et al. 2005; Meehan et al. 2001;
Myles et al. 2008; Sugimoto et al. 2001; Yehuda and Wurtman 1972), and an increase in core
temperature at warm (28 -37° C)ambient temperatures(Yehuda and Wurtman 1972; Myles
et al. 2008; Dafters 1995; Malberg and Seiden 1998).
D2Antagonist and METH-induced Hypothermia
Salmi et al.(1993), Elytab et al.(2001), and Chaperon et al.(2003) were able to
attenuate D2 agonist-induced hypothermia with a D2 antagonist, and Green et al.(2005)and
Yehuda and Wurtman(1972) were able to attenuate MDMA and AMPH-induced
hypothermia using a D2 antagonist at cool ambient temperatures. Based on these results, we
hypothesize we will be able to attenuate METH-induced hypothermia at 18° C with the D2
antagonist, RAC.
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D2Antagonist and METH-induced Hyperthermia
As stated above. Salmi et al.(1993), Elytab et al.(2001)and Chaperon(2003) were
able to attenuate a D2 agonist- induced decrease in core temperature by administering a D2
antagonist. These results implicate the D2 receptor as a mediator of hypothermia, and suggest
administration of a D2 antagonist will increase core temperature even when METH
administration leads to hyperthermia. However, Sugimoto et al.(2001)using PCA,Meehan
et al.(2001) using MDMA,and Bronstein and Hong(1995)using METH did not alter
METH or analog-induced hyperthermia with D2 antagonists at neutral (24-26.5° C)ambient
temperatures. In addition, Broening et al.(2005)and Bowyer et al.(1994) were able to block
METH-induced hyperthermia at neutral(24-26.5° C)ambient temperatures with a D2
antagonist. Since we plan to use METH,these results seem to favor an attenuation of METHinduced hyperthermia at neutral (24-26.5° C)ambient temperatures. We hypothesize we can
use the D2 antagonist, RAC,to block METH-induced hyperthermia at 24° C and 30° C. We
make this hypothesis, acknowledging compelling evidence exists that does not support this
hypothesis.
We expect D2 antagonist/METH core temperature to respond in much the same way
to neutral (24° C)and warm (30° C)ambient temperatures, based on the evidence that
METH alone caused an increase in core temperature in both neutral(24° C)and warm (30°
C)ambient temperatures.
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Methods and Materials
Animals
51 Sprague-Dawley rats, weighing between 300-325 grams at the beginning ofthe
experiment, were used. Rats were obtained from Harlan (Indianapolis,Indiana, USA). The
rats were housed singly, in stainless steel wire cages. The animals were kept on a twelvehour light/dark cycle with lights on at 7 AM. Food and water were ad-lib, except during
testing. The Institutional Animal Care and Use Committee(lACUC)ofthe University of
Mississippi approved all experimental procedures. All experimenters followed the Guide for
the Animal Care and Use of Laboratory Animals.
Surgery
Experimental subjects underwent a temperature transmitter(Mini-mitter model VMFH disc) implant surgery, that allows for telemetric core temperature measurement. The
transmitters were implanted in the peritoneal cavity ofthe animals. Ketamine(80 mg/kg),
xylazine(10 mg/kg), and atropine(5 mg/kg)were used as the pre-surgery anesthesia.
Secondary anesthesia was administered (0.1 mg/kg ketamine)ifthe animal flinched in
response to a toe pinch. Animals were given a 5 mg/kg dose ofketoprofen as a post-surgery
analgesic.
Drugs
(+)-Methamphetamine HCl(SIGMA; St. Louis, Missouri, USA)was dissolved in
0.09% saline. Experimental subjects received a 10 mg/kg dose of METH (salt calculation),
administered via an intraperitoneal injection. Raclopride tartrate (SIGMA; St. Louis,
Missouri, USA)was dissolved in 0.09% saline. Experimental subjects received 0.3, 0.6, or
1.2 mg/kg doses of RAC (free base calculation), administered via an intraperitoneal injection.
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In Experiment 1, four treatments were administered; sal, 0.3 mg/kg RAC,0.6 mg/kg RAC,
1.2 mg/kg RAC. Each animal received each ofthe four treatments once during the course of
the experiment. A Latin square design was used to control for sequencing effects. In
Experiment 2, five treatments were administered; sal/sal, sal/METH,0.3 RAC/METH,0.6
RAC/METH. 1.2 RAC/METH.Each animal received each ofthe five treatments once during
the course of the experiment.
Procedure
Upon arrival, animals were isolated for seven days. Following isolation, the animals
underwent the temperature transmitter implant surgery. Staples were removed ten days after
surgery. Experimental testing for both Experiment 1 and Experiment 2 began fourteen days
after surgery. Testing occurred on Mondays and Thursdays, beginning between 7 AM and 9
AM,for a total of five non-consecutive testing days. Testing occurred in an ambient
temperature-controlled enclosure. Three ambient temperatures were used in these
experiments: 18,24, and 30° C. The computer software program Rat Kitchen monitored the
animals’ core temperature telemetrically via the implanted transmitter. In Experiment 1, a
two-hour baseline reading ofthe animals’ core temperature was established at the beginning
oftesting. Two hours into testing, animals received one ofthe three RAC injections or a sal
injection. All injections were delivered in the experimental enclosure. Before and after drug
administration, the animals’ body temperature was recorded once per minute, via the Rat
Kitchen software. Total testing time was 7 hours. In Experiment 2, a two-hour baseline
reading of the animals’ core temperature was established at the beginning of testing. Two
hours into testing, animals received the first injection, which was one ofthe three doses of
RAC or a sal injection. Thirty minutes later, the animals received either a METH injection or
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a sal control injection. All injections were delivered in the experimental enclosure. Before
and after drug administration, the animals’ body temperature was recorded once per minute,
and recorded via Rat Kitchen. Total testing time was 7.5 hours.
Data Analysis
Experiment 1: Data were collected once per minute for 420 minutes, and recorded via
Rat Kitchen. The data were then averaged into fifteen-minute segments. A three-way analysis
of variance(ANOVA)was used to determine if RAC treatment had an effect on core
temperature. Time (-30, 0,30,60,180, and 270 minutes post-injection) and treatment(sal,
0.3 RAC,0.6 RAC, 1.2 RAC)were within subject factors, while ambient temperature (18,
24, and 30° C)was a between-subjects factor. Statistically significant results ofthe three-way
ANOVA were followed by a two-way ANOVA.The two-way ANOVA considered treatment
and ambient temperature at particular time points. Statistically significant results ofthe twoway ANOVA were followed by a one-way ANOVA,which considered treatment at
particular time points and ambient temperatures. A Newman- Keuls test was used when
necessary to determine significant differences between treatment groups.
Experiment 2: Data were collected once per minute for 450 minutes and recorded via
Rat Kitchen. The data were then averaged into fifteen- minute segments. A three- way
analysis of variance(ANOVA)was used to determine if METH plus RAC treatment had an
effect on core temperature. Time(0,30,60,180, and 300 minutes post-injection) and
treatment (sal7sal, sal/METH,0.3 RAC/METH,0.6 RAC/METH, 1.2 RAC/METH)were
within subject factors, while ambient temperature(18,24, and 30° C)was a between-subjects
factor. Statistically significant results of the three-way ANOVA were followed by a two-way
ANOVA. The two-way ANOVA considered treatment and ambient temperature at particular
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time points. Statistically significant results ofthe two-way ANOVA were followed by a one¬
way ANOVA,which considered treatment at particular time points and ambient
temperatures. A Newman-Keuls test was used when necessary to determine significant
differences between treatment groups.
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Results
In Experiment 2, RAC was administered 30 minutes prior to METH,and we
designated the time of RAC administration as time -30. We designated the time of METH
administration as time 0. In order to standardize the format of our figures, we carried this
time schedule into the figures for Experiment 1. However,time 0 in Experiment 1 is actually
30 minutes following RAC administration. Likewise in Experiment 1,30 minutes is actually
60 minutes post-RAC,45 minutes is 75 minutes post-RAC,60 minutes is 90 minutes postRAC,75 minutes is 105 minutes post-RAC, 180 minutes is 210 minutes post-RAC, and 270
minutes is 300 minutes post-RAC. These standardizations are in effect throughout the
Experiment 1 results section and the above distinctions should be made when reading the
results.
Experiment 1:
Each of the rats in this experiment received all doses ofRAC during the experiment.
Each rat received a sal dose, a 0.3 mg/kg,0.6 mg/kg, and a 1.2 mg/kg RAC dose. A threeway ANOVA resulted in significant main effects of ambient temperature [F(2,21)= 4.9, p<
.017], of treatment [F(3,63)=3.1, p<.034], oftime [F(4,84)=42.7, p<.000], and significant
interaction effects of ambient temperature x treatment [F(6,63)= 3.3, p<.007] and of ambient
temperature x time [F(8,84)=4.3, p<.000j. These significant interaction effects were
followed up with two-way ANOVAs at 0,60,180, and 270 minutes.
0 Minutes(30 minutes post-RAC)
A follow-up two-way ANOVA revealed a significant main effect ofambient
temperature [F (2,21)=4.9, p< .019], a significant main effect oftreatment[F (3,63)= 8.6,
p<.000], and a significant interaction effect ofambient temperature x treatment [F(6, 63)=
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4.0, p< .001]. This significant interaction effect was followed up with one-way ANOVAs at
18, 24, and 30° C. The one-way ANOVA at 18° C revealed a significant treatment effect[F
(3,21)= 18.6, p< .000]. Newman-Keuls analysis revealed the 1.2 mg/kg RAC dose was
significantly different fi-om all other treatment groups. No significant treatment effects were
found at 24° or 30° C(See figures 2 and 3 respectively).
60 Minutes(90 minutes post-RAC)
No significant main or interaction effects were found at 60 minutes. Although no
significant interaction effects were found. Figure 1 gave the impression that RAC had an
effect on core temperature in the time points surrounding 60 minutes. Therefore, additional
follow-up one-way ANOVAs were conducted at 30 minutes, 45 minutes,60 minutes, and 75
minutes in the 18° C ambient temperature.
30 Minutes(60 minutes post-RAC)
A sigmficant main effect oftreatment was found at 30 minutes [F(3,21)= 6.77,
p<.002j; Newman-Keuls post hoc analysis revealed the 1.2 mg/kg RAC group was
significantly different fi-om all other treatment groups.
45 Minutes(75 minutes post-RAC)
A significant main effect oftreatment was found at 45 minutes [F(3,21)= 4.11,
p<0.01]; Newman-Keuls post hoc analysis revealed the 1.2 mg/kg RAC group was
significantly different fiom the sal group.
75 Minutes(105 minutes post-RAC)
A significant main effect oftreatment was found at 75 minutes [F(3,21)= 3.53,
p<.03]; Newman-Keuls post hoc analysis revealed the 1.2 mg/kg RAC group was
significantly different fiom the sal group.
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180 and 270 Minutes(210 and 300 minutes post-RAC respecdvety)
A significant main effect of ambient temperature [F(2,21)= 6.0, p< .009] was found
at 180 minutes, and a significant main effect of ambient temperature [F(2,21)= 10.5, p<
.001]was found at 270 minutes. As no significant interaction effects were found at these time
points, no further analysis was conducted at these time points.
Experiment 2:
Each ofthe rats in this experiment underwent all five treatments; each treatment
consisted oftwo injections. All ofthe METH treated animals received 10 mg/kg METH.
The five treatments were as follows: a saline control (sal/sal) injection, a sal/METH
injection, a 0.3 mg/kg RAC/METH injection, a 0.6 mg/kg RAC/METH injection, and a 1.2
mg/kg RAC/METH injection. A three-way ANOVA resulted in significant main effects of
ambient temperature [F(2,24)= 10.5, p<0.001], oftreatment [F(4,96)= 16.8, p<0.000], oftime
[ F(4, 96)= 26.5, p<0.000], and significant interaction effects of ambient temperature x
treatment [F(8,96)-6.6, p<0.000], of ambient temperature x time[F(8,96)= 40.8, p<0.000],
of treatment x time [F(16,384)= 17.5, p<0.000], and of ambient temperature x treatment x
time [F(32, 384)= 8.6, p<0.000J.
Significant interaction effects were followed up with two-way ANOVAs at -30, 0,60,
180, and 300 minutes post- treatment. A significant main effect of ambient temperature [F
(2,24)= 3.6, p<0.05] was found at -30 minutes; a significant main effect oftreatment[F
(4,96)=6.4, p<0.000] was found at 0 minutes following treatment. No interaction effects were
seen at these two time points, so no further analysis was conducted at these time points.
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60 minutes
At 60 minutes post-treatment, a two-way ANOVA revealed a significant main effect
of ambient temperature [F (2,24)= 52.6, p<0.000] and a significant main effect oftreatment
[F (4,96)= 11.5, p<0.000], as well as a significant interaction effect of ambient temperature x
treatment [F (8,96)= 18.6, p<0.000]. This significant interaction effect was followed up with
a one-way ANOVA at 18° C, which revealed a significant treatment effect[F (4,36)= 17.8,
p<0.000]; Newman-Keuls analysis showed all treatment groups had a significantly lower
core temperature compared to the sal/ sal group. The sal/METH treatment group had a
significantly lower core temperature than the sal/sal group, but a significantly higher core
temperature than the RAC/METH treatment groups. These results indicate a METH-induced
hypothermia that is enhanced by treatment with RAC. The RAC/METH treatment groups
were not significantly different fi-om each other(Figure 4).
At 24° C,a one-way ANOVA revealed a significant treatment effect[F(4,28)= 3.6,
p<0.02]; Newman-Keuls analysis showed the sal/METH treatment group had a significantly
higher core temperature compared to the sal/ sal group and the 1.2 mg/kg RAC/METH
treatment group. The 0.3 and 0.6 mg/kg RAC treatment groups were not significantly
different fi-om the sal/METH treatment group (Figure 5). These results indicate a METHinduced hyperthermia that is only attenuated by the 1.2 mg /kg RAC dose.
At 30° C,a one-way ANOVA revealed a significant treatment effect[F(4,32)= 24.2,
p<0.000]; Newman-Keuls analysis showed all other treatment groups had a significantly
higher core temperature compared to the sal/sal group. However,the 0.6 mg /kg RAC/METH
treatment group, but not the 0.3 mg/kg RAC/METH or 1.2 mg/kg RAC/METH treatment
group, had a significantly lower core temperature compared to the sal/METH treatment
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group (Pigure 6). These results indicate a METH-induced hyperthermia that is only
attenuated by the 0.6 mg /kg RAC dose. However,the 0.6 RAC/METH treatment group was
still significantly different from sal/sal, so the hyperthermia was not totally attenuated.
180 minutes
At 180 minutes post-treatment, a two-way ANOVA revealed a significant main effect
of treatment [F (4, 96)= 40.6, p<0.000] and a significant interaction effect oftreatment x
ambient temperature [F (8,96)= 2.3, p<0.02].
This significant interaction effect was followed up with one- way ANOVAs at 18° C,
24° C,and 30° C, which revealed significant treatment effects:[F (4,36)= 5.2, p<0.002],[F
(4,28)= 14.9, p<0.000],[F (4,32)= 23.3, p<0.000] respectively. NevwnanKeuls analysis
showed the sal/METH,0.3 mg/kg RAC/METH,0.6 mg/kg RAC/METH,and 1.2 mg/kg
RAC/METH treatment groups at all three ambient temperatures were not significantly
different from each other, but had a significantly higher core temperature compared to the
sal/sal treatment group (Figures 4,5, and 6).
300 minutes
At 300 minutes post-treatment, a two-way ANOVA revealed a significant main effect
of treatment[F (4,96)= 41.8, p<0.000] and a significant interaction effect of ambient
temperature x treatment [F(8,96)- 2.8 p<0.008].
This significant interaction effect was followed up with one-way ANOVAs at 18° C,
24° C, and 30° C, which revealed significant treatment effects:[F(4,36)= 12.9, p<0.000],[F
(4,28)= 7.6, p<0.000],[F (4, 32)= 25.5, p<0.000] respectively. Newman-Keuls analysis
showed the sal/METH,0.3 mg/kg RAC/METH,0.6 mg/kg RAC/METH,and 1.2 mg/kg
RAC/METH treatment groups at all three ambient temperatures were not significantly
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different from each other, but had significantly higher core temperature compared to the
sal/sal treatment group (Figures 4, 5, and 6).
Experiment 1 and 2 Comparison
In Experiment 1, we found the 1.2 mg/kg dose of RAC caused a decrease in core
temperature at 18° C (Figure 1); in Experiment 2 we found the 0.3 mg/kg,0.6 mg/kg, and 1.2
mg/kg doses of RAC plus 10 mg/kg METH caused a decrease in core temperature at 18° C
(Figure 4). We performed a series of analyses to compare the 1.2 mg/kg doses ofRAC ofthe
two experimental groups, in order to determine if 1.2 mg/kg RAC plus 10 mg/kg METFl
caused a significant decrease in core temperature greater than that of RAC alone. Two-way
ANOVAs were performed at 30,60, and 90 minutes post-treatment; the two experimental
groups, RAC alone and RAC plus METH (experiment), were between subject factors, while
the sal and 1.2 mg/kg RAC treatment(treatment) were within factors.
At 30 minutes post-treatment, we found a significant main effect oftreatment
7(1,16)= 45.4, p<0.001], and a significant interaction effect oftreatment x experiment[F
(1,16)= 32.3, p< 0.000]. At 60 minutes post-treatment, we found a significant main effect of
experiment [F(l,16)= 12.8, p< 0.002], a significant main effect oftreatment [F(l,16)= 143.0,
p<0.000], and a significant interaction effect ofexperiment x treatment[F(l,16)= 117.4,
p<0.000]. At 90 minutes post-treatment, we found a significant mam effect ofexperiment
[F(l,16)= 10.0, p<0.006], and a significant main effect oftreatment [F(l,16)= 23.2,
p<0.000], but no significant interaction effect.
The significant interaction effects at 30 and 60 minutes were followed up with one
way ANOVAs. At 30 minutes post-treatment, the sal treatments ofthe experimental groups
were not significantly different from each other; however,the RAC treatments were
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significantly different [F(l,16)-l 7.3, p<0.001]. At 60 minutes post-treatment,the sal
treatments were not significantly different finm each other; however,the RAC treatments
were significantly different [F(l,16)- 55.4, p<0.000].
These results indicate that RAC/METH decreases core temperature more than RAC alone at
18°C.
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Discussion

Evaluation ofResearch Hypothesis
We conducted Experiment 1 in order to determine if RAC alone had an effect on core
temperature. We hypothesized that RAC would have no effect on core temperature at any of
the ambient temperatures; however, we found the 1.2 mg/kg dose ofRAC caused a decrease
in core temperature at 18° C. This unexpected result has not been documented in the
literature. RAC alone had no effect on core temperature at 24® C or 30° C.
In Experiment 1, we hypothesized we would be able to attenuate METH-induced
hypothermia with RAC at cool(18° C)ambient temperatures. Our results do not support this
hypothesis; in fact, the opposite is true. Sbcty minutes post-METH treatment, all three RAC
(0.3,0.6,1.2 mg/kg)/METH treated groups had significantly lower core temperature compared
to sal/sal, but also had a significantly lower core temperature compared to sal/METH. METH
alone caused a decrease in core temperature at 18° C,but RAC/METH caused an even bigger
decrease in core temperature. A follow-up comparison between RAC alone and RAC/METH
at 18° C demonstrated the hypothermia caused by RAC/METH cannot be explained by RAC
alone. However,these data suggest that the combined effects ofRAC/METH at 18° C may
be additive.
The neutral ambient temperature (24°C)category had conflicting information fi'om
the literature, but we hypothesized we would be able to attenuate METH-induced
hyperthermia with RAC. We were aware that strong evidence existed that did not support our
hypothesis. We were able to attenuate METH-induced hyperthermia with the 1.2 mg/kg dose
of RAC at sixty minutes post-treatment, thereby supporting our hypothesis.
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We hypothesized we would see sunilar results from the neutral(24° C)and warm
(30° C)ambient temperature categories. At 30° C,sixty minutes post-treatment, we saw
some attenuation of METH-induced hyperthermia with the 0.6 mg/kg dose ofRAC;this was
not complete attenuation as the 0.6 mg/kg RAC/METH group was still significantly different
from sal/sal. Our hypothesis was supported as the METH-induced hyperthermia was
attenuated, although not totally. Interestingly, this effect was only seen at the intermediate
RAC dose; the 0.6 mg/kg dose lowered core temperature while neither the 0.3 nor the 1.2mg/kg doses of RAC had an effect on the METH-induced hyperthermia at 30° C.
We only made hypotheses regarding the time directly following drug administration
(60 minutes post-METH); however, we saw a later hyperthermic peak at 180 minutes that
was consistent in the sal/METH,0.3 mg/kg RAC/METH,0.6 mg/kg RAC/METH,and 1.2
mg/kg RAC/METH treatment groups and in all three (18,24, and 30° C)ambient
temperatures. Myles et al.(2008)achieved a similar METH effect at different ambient
temperatures, and suggested two separate mechanisms are at work directly following METH
administration (60 minutes post-METH)and at later time points(180 minutes post-METH).
Pre-treatment with RAC had no effect on this later hyperthermic peak, perhaps because the
half-life of RAC is too short, or because another mechanism or some other system besides
the D2 receptor is at work at these later time points. For the purposes ofExperiment 1 and
Experiment 2, we focused on the time directly following drug administration(60 minutes
post-METH).
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Comparison with Literature
Experiment 1:
Our results from Experiment 1 at 18° C were unique; studies(Salmi et al. 1993;
Elytab et al. 2001)concerning RAC’s effects on core temperature were done at 24° C,and
these studies determined RAC had no significant effect on core temperature. However,no
literature addresses RAC’s effects on core temperature at cool(18°C)ambient temperatures,
and we determined the 1.2 mg/kg dose ofRAC caused a decrease in core temperature.
Experiment 1’s unexpected hypothermic effect of RAC alone is inconsistent with the
findings of Salmi et al.(1993), Elytab et al.(2001), and Chaperon et al.(2003), who showed
the D2 receptor is a mediator of hypothermia. Our result of RAC-induced hypothermia
indicates that at 18° C the D2 receptor may be involved in heat production. However, at 24
and 30° C, RAC had no effect on core temperature, which is consistent with the findings of
Salmi et al.(1993), Elytab et al.(2001), and Chaperon et al.(2003).
Experiment 2:
Our results of Experiment 2 at 18° C are not consistent with findings in the literature.
Salmi et al.(1993), Elytab et al.(2001), and Chaperon et al.(2003)found administration of a
D2 antagonist prevented the hypothermia caused by a D2 agonist, and Green et al.(2005)
and Yehuda and Wurtman (1972) were able to attenuate MDMA and AMPH-induced
hypothermia at cool ambient temperatures with a D2 antagonist. We found pre-treatment
with RAC enhanced METH-induced hypothermia. Experiment 2’s puzzling result of
enhanced hypothermia at 18° C in all three (0.3,0.6, and 1.2 mg/kg)RAC/METH treatment
groups requires re-evaluation of our research hypothesis. This result does not agree with the
literature, nor did we predict this outcome; however. Green et al.(2005)and Yehuda and
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Wurtman (1972) used MDMA and AMPH (respectively), while we used METH and found a
totally different result.
The results of Experiment 2 at 24° C are consistent with our research hypothesis and
the findings of Bowyer et al.(1994)and Broening et al.(2005)who were able to attenuate
METH-induced hyperthermia at neutral(24 and 26.5° C respectively) ambient temperatures
using a D2 antagonist; our results were also consistent with Yehuda and Wurtman(1972)
who were able to attenuate AMPH-induced hyperthermia using a D2 antagonist. Bronstein
and Hong (1995), Meehan et al.(2001), and Sugimoto et al.(2001)were not able to attenuate
METH, MDMA,and PCA (respectively)- induced hyperthermia. The literature concerning
attenuation of METH-induced hyperthermia at neutral ambient temperatures(24-26.5° C)is
conflicting, but our result of attenuation of METH-induced hyperthermia with RAC at 24° C
lends support to our hypothesis that METH-induced hyperthermia can be attenuated by pre
treatment with a D2 antagonist.
As none of the literature addressed treatment of METH-induced hyperthermia with a
D2 antagonist at a warm (30° C)ambient temperature, we considered the above-mentioned
neutral (24-26.5° C)ambient temperature literature when making a research hypothesis for
the 30° C ambient temperature. Our results at the warm ambient temperature are somewhat
consistent with the findings in the neutral(24-26.5° C)literature, as we had some, but not
total, attenuation of METH-induced hyperthermia with the 0.6 mg/kg dose of RAC,while
neither the 0.3 nor 1.2 mg/kg dose ofRAC had an effect on the METH-induced
hyperthermia.
However, some re-evaluation of our research hypothesis is necessary as we were able
to partially attenuate METH-induced hyperthermia with the 0.6 mg/kg dose of RAC,but
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neither the 0.3 mg/kg nor the 1.2 mg/kg dose of RAC had any effect on the METH-induced
hyperthermia. Perhaps the 0.3 mg/kg dose of was too small to effectively block the D2
receptor, while the 1.2 mg/kg dose of RAC was too large and began affecting other receptors
or even other systems, instead of targeting the D2 receptor specifically.
We chose RAC for this experiment because it has a very high affinity for the D2
receptor and a very low affinity for the D1 receptor (K,-= 1.07 nM for D2 versus 3000 nM for
D1), for the serotonin 1A and 2 receptors(Kj>1000 nM for both)and the norepinephrine
alpha 1 and beta 1 receptors(K,= 967 nM and 1000 nM respectively)(Millan et al. 1998).
But, no drug has one hundred percent selectivity for a receptor, so RAC could be affecting
other receptors or systems, especially at higher doses.
This study should be repeated at 30° C with additional RAC doses(such as 0.4,0.8,
and 1.0 mg/kg)to more accurately determine the dose-response relationships.
Our results fi*om Experiment 2, while not always consistent with the literature, are
internally consistent; at both 18° C and 24° C,RAC caused a decrease in core temperature.
Since D2 blockade caused further decrease in core temperature at 18° C and 24° C,rather
than blockade of hypothermia as the direct D2 agonist(Salmi et al. 1993; Elytab et al. 2001;
Chaperon et al.(2003)) literature indicates, our results suggest neurotransmitter interactions
are involved in core temperature control during METH administration.
Neurotransmitter Interaction
In these experiments, we only investigated the D2 receptor and how a D2 antagonist
alone affects core temperature, and how a D2 antagonist affects METH-induced changes in
core temperature. However, as discussed previously, temperature control is a complex
process involving many body systems, with the goal of maintaining homeostasis. Other
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dopamine receptors, neurotransmitter systems, and hormone interactions are all involved in
temperature regulation in the body.
Sprague et al.(2008)reported thyroid hormone increases core temperature, while lack
of thyroid hormone decreases core temperature. Salmi et al.(1993)and Chaperon et al.
(2003)reported D1 receptor agonists cause hypothermia. Salmi and Ahlenius(1998)and
Gudelsky et al.(1986)reported serotonin 5-HTlA receptor agonists cause hypothermia.
while 5-HT2 receptor agonists cause hyperthermia. Ootsuka et al.(2006)reported
thermogenesis in brown adipose tissue is increased by 5-HT2 receptor activation and
decreased by 5-HTl A receptor activation. Depocas et al.(1978)reported norepinephrine
alone caused an increase in core temperature, while administration ofa norepinephrine alpha
1 receptor antagonist caused a decrease in core temperature.
All of the above-mentioned receptors are aJBfected by stimulant administration; METH
and its analogs affect the release of not only dopamine, but also serotonin and
norepinephrine. METH and AMPH cause the ranked release of norepinephrine > dopamine >
serotonin (Crespi et al.(1997);(Rothman et al.(2001); Wee et al.(1997)), while MDMA and
PCA cause the ranked release of serotonin > both dopamine and norepinephrine(Johnson et
al. 1987; Rothman and Baumann 2003; Sanders-Bush et al. 1975; Crepsi et al. 1997).
Therefore, differences in neurotransmitter release could account for the differences between
our experiment, in which D2 blockade enhanced METH-induced hypothermia, and the
literature, in which D2 blockade attenuated METH or analog-induced hypothermia at 18° C.
Differences in neurotransmitter release could also account for the differences between
our experiment and the findings of Bowyer et al.(1994), Broening et al.(2005), and Yehuda
and Wurtman (1972)in which D2 blockade reduced METH-induced hyperthermia, and the
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literature using METH analogs(Bronstein and Hong(1995); Meehan et al.(2001); Sugimoto
et al.(2001)) in which D2 blockade did not affect analog-induced hyperthermia at 24 and 30°
C.
Potential Methodological Causesfor Discrepancies
While neurotransmitter interaction may be an important factor in the discrepant
effects on core temperature during D2 antagonist/METH analog administration, experimental
conditions should be taken into account as well. Methodological variations might be the
cause of discrepancies betw'een our results and those ofthe literature. As stated above, we
measured core temperature telemetrically in order to avoid unwanted increases in core
temperature and reported enhanced hypothermia by RAC/METH treatment at 18° C, while
Yehuda and Wurtman (1972) measured core temperature via a rectal probe and reported
attenuation of hypothermia by D2 antagonist/ AMPH treatment at 4° C. Also, several
different D2 antagonists were used in the literature, so perhaps this difference caused the
discrepancies in our results. Finally, we used Sprague-Dawley rats housed singly, vdiich was
similar to the conditions of Bowyer et al.(1994), but not Broening et al.(2003), however our
results were consistent with the findings of both ofthese studies, thereby eliminating housing
conditions as potential causes for discrepancies.
Future Studies
In the future, more studies should be done to investigate norepinephrine and serotonin
and their roles in core temperature control; both are important neurotransmitters involved in
core temperature. As stated above, METH causes the release of both ofthese
neurochemicals, as well as dopamine. Therefore, norepinephrine and serotonin might be
interacting with dopamine and affecting core temperature following METH administration.
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Also in the future, more work should be done investigating different D2 antagonists’
effects on core temperature at cold ambient temperatures. Since RAC alone caused a
decrease in core temperature at 18® C, perhaps other D2 antagonists will also cause a
decrease in core temperature. The exact mechanism ofthe D2 receptor that caused
hypothermia after being blocked by RAC is unknown, but this interesting result should be
investigated further.
The RAC/METH dose-response curve at 30® C is another interesting result that
should be investigated further. As stated above, it would be interesting to see ifthis result
could be duplicated and it would be interesting to add more doses of RAC in the 0.3-0.6
mg/kg range, and in the 0.6-1.2 mg/kg range to determine ifa dose-response curve is actually
occurring.
Finally, METH,in combination with a D2 antagonist, seems to have a much different
effect on core temperature than of its analogs in combination with a D2 antagonist, therefore
more receptor antagonist/METH studies involving core temperature should be done.
METH has become one ofthe most widely abused substances in the United States
(National Institute on Drug Abuse 1999), and its effects on core temperature are important to
understand. These experiments add to the literature by expandmg our understanding of the
D2 receptor’s involvement m METH-induced core temperature changes at varying ambient
temperatures.
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Figure Captions
Figure 1: 1.2 mg/kg R.AC treatment group was significantly different fiom all other
treatment groups at 30 minutes(60 minutes post-RAC),45 minutes(75 minutes post-RAC),
and 75 minutes(105 minutespost-RAC)(€). 0.3 mg/kg RAC treatment was not significantly
different from sal/sal; 0.6 mg/kg RAC treatment was not significantly different from sal/sal.

Figure 2: None of the RAC treatment groups were significantly different from sal/sal at any
time point.

Figure 3: None of the RAC treatment groups were significantly different from sal/sal at any
time point.

Figure 4i Sal/ METH treatment group and all three RAC(0.3 mg/kg,0.6 mg/kg, 1.2
mg/kg)/METH treatment groups were significantly different from sal/sal(*)at 60 min postMETH; all RAC treated groups were significantly different from sal/sal and sal/METH(**)
at 60 min post-METH; the sal/METH treatment group and all three RAC/METH treatment
groups were significantly different from sal/sal(*)at 180 min post-METH;the sal/METH
treatment group and all three RAC/METH treatment groups were significantly different from
saEsal(*) at 300 min post-lVlETH.

Figure 5:sal/METH was significantly different from sal/sal(+)at 60 min post-METH; 1.2
RAC/METH was significantly different from sal/METH (#)at 60 min post-METH; the
sal/METH treatment group and all three RAC/METH treatment groups were significantly
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different from sal/sal (*) at 180 min post-METH; the sal/METH and all three RAC/METH
treatment groups were significantly different from sal/sal(*)at 300 min post-METH.

Figure 6: The sal/METH treatment group and all three RAC/METH treatment groups were
significantly different from sal/sal (*) at 60 min post-METH; 0.6 RAC/METH was
significantly different from sal/METH(@)at 60 min post-METH;the sal/METH treatment
group and all three RAC/METH treatment groups were significantly different fixim sal/sal(*)
at 180 min post-METH; the sal/METH treatment group and all three RAC/METH treatment
groups were significantly different from sal/sal(*)at 300 min post-METH.
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Figure 4
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Figure 5
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